I se suʻesuʻega na lolomiina i le lomiga o Novema o le Journal of Personalized Medicine, na suʻesuʻeina e le au suʻesuʻe le mea e tupu pe a ave faʻatasi ma isi vailaʻau e manaʻomia. le enzyme tutusa. O tagata na ave ia le itiiti ifo ma le tasi o nei opioids ma le itiiti ifo ma le tasi le isi vailaʻau e tauva mo lena enzyme e maualuga atu le averesi o tupe faʻaalu i tausaga taʻitasi ma e sili atu le averesi o le faʻaaogaina o le opioid i aso taitasi nai lo tagata na faʻaaogaina se tasi o nei opioids ae leai ni vailaʻau faʻafesoʻotaʻi. E le gata i lea, na maua e tagata suʻesuʻe o tagata taʻitoʻatasi na ave a itiiti ifo ma le tasi o nei opioids ma le itiiti ifo ma le tasi le vailaʻau faʻafesoʻotaʻi e masani lava ona sili atu le lamatia o isi faʻalavelave faʻaleagaina, faʻavae i luga o le TRHC's MedWise Science, lea e iloiloina le lisi atoa o vailaʻau a le tagata maʻi pe a suʻesuʻeina mo fualaau faʻasaina. faafitauli.
"Faatasi ai ma MedWise Science, e mafai ona matou iloa po o ai e maualuga atu le lamatiaga o taunuuga le lelei ona o fegalegaleaiga fualaau faasaina," o le tala lea a le Taitaifono ma le Pule Sili o le TRHC Calvin H. Knowlton, PhD. "O le suia o faʻataʻitaʻiga o loʻo iai nei e puipuia ai fegalegaleaiga o fualaau faasaina e mafai ona faʻaleleia ai le saogalemu o vailaʻau, e ono faʻaleleia ai le aoga o opioids mo nisi tagata gasegase aʻo faʻaitiitia iʻuga le lelei o tagata maʻi ma latou tau faʻatatau."
O se suʻesuʻega eseʻese i le Journal of Palliative Medicine na faʻaogaina ai le MedWise Science ma ana meafaigaluega e lagolago ai filifiliga faʻapitoa e iloilo ai faʻamatalaga faʻavae e fesoʻotaʻi ma le opioid metabolism. O le suʻesuʻega e faʻaalia ai e mafai e fomaʻi o loʻo faʻaogaina faʻamatalaga pharmacogenomic e mafai ona fesoasoani i fomaʻi e faʻaleleia le saogalemu o vailaʻau. E tusa ai ma le suʻesuʻega, 85% o fomaʻi na faʻaalia o meafaigaluega e lagolago ai filifiliga na faʻaleleia atili ai le lelei o le tausiga o maʻi mo tagata mamaʻi na ave opioids.
"O le suʻesuʻeina o kenera e aumaia ai le faʻapitoa ma le saʻo i le ogatotonu o le saogalemu o vailaʻau," o le tala lea a Jacques Turgeon, BPharm, PhD, TRHC Ofisa Sili Saienitisi ma le Pule Sili o le Precision Pharmacotherapy Research and Development Institute. "O le lagolago a le falemaʻi e ala i le MedWise Science e fesoasoani i fomaʻi e talepe i lalo faʻamaumauga o kenera ma faʻaauupegaina i latou i fautuaga aoga e aloese ai mai faʻafitauli o vailaʻau."
OA MEA E AVEA MAI LENEI TUSI:
- People who took at least one of these opioids and at least one other drug that competes for that enzyme had higher average yearly medical expenses and a greater average daily opioid intake than people who took at least one of these opioids but no interacting drugs.
- Additionally, researchers found that individuals who took at least one of these opioids and at least one interacting drug generally had a greater risk of other adverse drug events, based on TRHC’s MedWise Science, which considers a patient’s entire medication list when assessing for drug-related problems.
- In a study published in the November issue of the Journal of Personalized Medicine, researchers examined what happens when common opioids such as hydrocodone, oxycodone, codeine, and tramadol, which need a particular enzyme to activate pain relief, are taken with other medications that require the same enzyme.
